Heron Therapeutics, Inc. v. Mylan Pharmaceuticals Inc.
| Heron Therapeutics, Inc. |
| Mylan Pharmaceuticals Inc. |
| 1:2023cv01015 |
| September 15, 2023 |
| US District Court for the District of Delaware |
| William C Bryson |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. ยง 271 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on November 8, 2023. A more recent docket listing may be available from PACER.
| Document Text |
|---|
Filing 10
ORDER: A Telephonic Scheduling Conference is set for 11/28/2023 at 10:00 AM before Judge William C. Bryson. Joint Status Report due by 11/22/2023. (See Order for further details and deadlines). Signed by Judge William C. Bryson on 11/8/2023. (rlr)
|
|
Filing 9
ORDER granting D.I. #8 Motion to Appear Pro Hac Vice of Bruce M. Wexler, Isaac S. Ashkenazi, Christopher P. Hill, and Mark Russell Sperling. Signed by Judge William C. Bryson on 10/19/2023. (apk)
|
| Filing 8 MOTION for Pro Hac Vice Appearance of Attorney Bruce M. Wexler, Isaac S. Ashkenazi, Christopher P. Hill, and Mark Russell Sperling - filed by Heron Therapeutics, Inc.. (Tigan, Jeremy) |
| Filing 7 WAIVER OF SERVICE returned executed by Heron Therapeutics, Inc.: For Mylan Pharmaceuticals Inc. waiver sent on 10/3/2023, answer due 12/4/2023. (Tigan, Jeremy) |
| Case Assigned to Judge William C. Bryson of the United States Court of Appeals for the Federal Circuit (due to related case). Please include the initials of the Judge (WCB) after the case number on all documents filed. (rjb) |
| Filing 6 Summons Issued as to Mylan Pharmaceuticals Inc. on 9/15/2023. (vfm) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Heron Therapeutics, Inc.. (vfm) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,561,229 B2 ;9,808,465 B2 ;9,974,742 B2 ;9,974,793 B2 ;9,974,794 B2. (vfm) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 08/04/2023. Date of Expiration of Patent: 09/18/2035.Thirty Month Stay Deadline: 2/4/2026. (vfm) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (vfm) |
| Filing 1 COMPLAINT for ANDA/PATENT INFRINGEMENT filed against Mylan Pharmaceuticals Inc. ( Filing fee $ 402, receipt number ADEDC-4225625.) - filed by Heron Therapeutics, Inc.. (Attachments: #1 Exhibit A-I, #2 Civil Cover Sheet) (vfm) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
| Search for this case: Heron Therapeutics, Inc. v. Mylan Pharmaceuticals Inc. | |
|---|---|
| Search News | [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ] |
| Search Web | [ Unicourt | Legal Web | Google | Bing | Yahoo | Ask ] |
| Plaintiff: Heron Therapeutics, Inc. | |
| Represented By: | Jack B. Blumenfeld |
| Represented By: | Jeremy A. Tigan |
| Search News | [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ] |
| Search Finance | [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ] |
| Search Web | [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ] |
| Defendant: Mylan Pharmaceuticals Inc. | |
| Search News | [ Google News | Marketwatch | Wall Street Journal | Financial Times | New York Times ] |
| Search Finance | [ Google Finance | Yahoo Finance | Hoovers | SEC Edgar Filings ] |
| Search Web | [ Unicourt | Justia Dockets | Legal Web | Google | Bing | Yahoo | Ask ] |
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
